changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Certain BTG products may not be available within the chosen location and indications may differ from your country's approved use.
For Medical questions regarding any BTG products, please contact email@example.com
Please find below a list of our press releases.
19 Jun 2018
Starting with the 2018/19 financial year, BTG will change its presentational currency to the US Dollar. This change is reflective of the fact that the majority of the Group’s revenues and a significant proportion of its operating costs are now denominated in US Dollars. Historical US Dollar income statements, on an IFRS and Adjusted basis, and selected product sales information are presented in the document below.
15 Jun 2018
BTG plc (LSE: BTG), the global specialist healthcare company, notes that the US Food & Drug Administration’s (FDA’s) Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee yesterday voted against the approval of the Elevair™ Endobronchial Coil System for the treatment of people with severe emphysema.
11 Jun 2018
BTG plc (LSE: BTG), the global healthcare company, today announces the start of ELEVATE: A randomizEd ControlLed Study of PnEumRx™ Endobronchial Coil System (Coils) Versus Standard of Care Medical MAnagement in the Treatment of Subjects with Severe Emphysema.
15 May 2018
BTG plc (LSE: BTG), the global specialist healthcare company, today announces its final results for the year ended 31 March 2018.
27 Apr 2018
BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.
5 Apr 2018
London, UK, 5 April 2018: BTG plc (LSE: BTG), the global healthcare company, provides the following update for the year ended 31 March 2018.
BTG has delivered a good financial performance for the year, with revenue in line with expectations.
21 Feb 2018
February 28, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, announced the first patient in Latin America in Mexico was treated with TheraSphere® – a treatment for hepatic neoplasia that delivers powerful radiation to tumour cells and minimizes the exposure to healthy tissue.
23 Jan 2018
BTG plc (LSE: BTG) the specialist healthcare company, today announces the appointment of Anne Thorburn as a non-executive director of the Board and member of the Audit Committee.
14 Dec 2017
BTG plc (LSE: BTG), the global specialist healthcare company, today highlights the commencement of the KNOCOUT PE study. The KNOCOUT PE study will measure how hospitals and patients are benefitting from a new standard of care in the treatment of Pulmonary Embolism utilizing EKOS® therapy with faster, and even safer protocols, proven effective in the OPTALYSE PE study. Presented in May, the OPTALYSE PE study found pulmonary embolism (PE) can be treated effectively with EKOS® therapy over a much shorter period and at safer thrombolytic doses far below the previous standard.
27 Nov 2017
BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.